Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2429-2434

  Ogiso, Yasunari ^a   Tomida, Akihiro ^a   Lei, Shuhong ^a   Omura, Satoshi ^b   Tsuruo, Takashi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO INSTITUTE   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; LACTACYSTIN; PROTEASOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COLON CARCINOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ACETYLCYSTEINE; ANIMALS; ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; CELL CYCLE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; GLUCOSE; HUMANS; IMMUNOBLOTTING; ISOENZYMES; METHOTREXATE; MICE; MICE, NUDE; MULTIENZYME COMPLEXES; NEOPLASM TRANSPLANTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; TIME FACTORS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0034193276     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Washington DC), 240: 177-184, 1988.
2. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
3. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
4. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
5. Shim, H., Chun, Y. S., Lewis, B. C., and Dang, C. V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. USA, 95: 1511-1516, 1998.
6. Reed, J. C., Miyashita, T., Takayama, S., Wang, H. G., Sato, T., Krajewski, S., Aime-Sempe, C., Bodrug, S., Kitada, S., and Hanada, M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem., 60: 23-32, 1996.
7. Hannun, Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 89: 1845-1853, 1997.
8. Tomida, A., and Tsuruo, T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des., 14: 169-177, 1999.
9. Shen, J., Hughes, C., Chao, C., Cai, J., Bartels, C., Gessner, T., and Subjeck, J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. USA, 84: 3278-3282, 1987.
10. Hughes, C. S., Shen, J. W., and Subjeck, J. R. Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res., 49: 4452-4454, 1989.
11. Yun, J., Tomida, A., Nagata, K., and Tsuruo, T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol. Res., 7: 583-590, 1995.
12. Tomida, A., Yun, J., and Tsuruo, T. Glucose-regulated stresses induce resistance to camptothecin in human cancer cells. Int. J. Cancer, 68: 391-396, 1996.
13. Lee, A. S. Mammalian stress response: induction of the glucose-regulated protein family. Curr. Opin. Cell. Biol., 4: 267-273, 1992.
14. Lee, A. S. The accumulation of three specific proteins related to glucose-regulated proteins in a temperature-sensitive hamster mutant cell line K12. J. Cell. Physiol., 106: 119-125, 1981.
15. Tomida, A., Suzuki, H., Kim, H-D., and Tsuruo, T. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene, 13: 2699-2705, 1996.
16. Koong, A. C., Chen, E. Y., and Giaccia, A. J. Hypoxia causes the activation of nuclear factor KB through the phosphorylation of IκBα on tyrosine residues. Cancer Res., 54: 1425-1430, 1994.
17. Koong, A. C., Chen, E. Y., Mivechi, N. F., Denko, N. C., Stambrook, P., and Giaccia, A. J. Hypoxic activation of nuclear factor-κB is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res., 54: 5273-5279, 1994.
18. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
19. Wang, C. Y., Cusack, J. C., Jr., Liu, R., and Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med., 5: 412-417, 1999.
20. Bentires-Alj, M., Hellin, A. C., Ameyar, M., Chouaib, S., Merville, M. P., and Bours, V. Stable inhibition of nuclear factor κB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res., 59: 811-815, 1999.
21. Shen, J. W., Subjeck, J. R., Lock, R. B., and Ross, W. E. Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol. Cell. Biol. 9: 3284-3291, 1989.
22. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
23. Froelich-Ammon, S. J., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
24. Beck, W. T., Danks, M. K., Wolverton, J. S., Chen, M., Granzen, B., Kim, R., and Suttle, D. P. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv. Pharmacol., 29B: 145-169, 1994.
25. Chen, A. Y., and Liu, L. F. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat. Res., 73: 263-281, 1994.
26. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
27. Coux, O., Tanaka, K., and Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 65: 801-847, 1996.
28. L. Cancer Res., 56: 2161-2166, 1996.
29. Omura, S., Matsuzaki, K., Fujimoto, T., Kosuge, K., Furuya, T., Fujita, S., and Nakagawa, A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot., 44: 117-118, 1991.
30. Omura, S., Fujimoto, T., Otoguro, K., Matsuzaki, K., Moriguchi, R., Tanaka, H., and Sasaki, Y. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot., 44: 113-116, 1991.
31. 1 cell cycle arrest in cancer cells. J. Cell. Physiol., 180: 97-104, 1999.
32. Bush, K. T., Goldberg, A. L., and Nigam, S. K. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J. Biol. Chem., 272: 9086-9092, 1997.
33. Tsubuki, S., Saito, Y., Tomioka, M., Ito, H., and Kawashima, S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem., 119: 572-576, 1996.
34. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Washington DC), 268: 726-731, 1995.
35. Sullivan, D. M., Latham, M. D., and Ross, W. E. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res., 47: 3973-3979, 1987.
36. Hsiang, Y. H., Wu, H. Y., and Liu, L. F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res., 48: 3230-3235, 1988.
37. Kroll, D. J., and Rowe, T. C. Phosphorylation of DNA topoisomerase II in a human tumor cell line. J. Biol. Chem., 266: 7957-7961, 1991.
38. Doyle, L. A. Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother. Pharmacol., 34: S32-S40, 1994.
39. Kimura, H., Braun, R. D., Ong, E. T., Hsu, R., Secomb, T. W., Papahadjopoulos, D., Hong, K., and Dewhirsl, M. W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res., 56: 5522-5528, 1996.
40. Hochstrasser, M. Ubiquitin-dependent protein degradation. Annu Rev. Genet., 30: 405-439, 1996.
41. Hershko, A., and Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 67: 425-479, 1998.
42. Nakajima, T., Monta, K., Ohi, N., Arai, T., Nozaki, N., Kikuchi, A., Osaka, F., Yamao, F., and Oda, K. Degradation of topoisomerase IIα during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J. Biol. Chem., 271: 24842-24849, 1996.
43. Baumeister, W., Walz, J., Zuhl, F., and Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell, 92: 367-380, 1998.
44. Ogiso, Y., Tomida, A., Kim, H. D., and Tsuruo, T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem. Biophys. Res. Commun., 258: 448-452, 1999.
45. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999.